Malignant pleural mesothelioma is an uncommon cancer for which the maj
or risk factor is prior asbestos exposure. During the past decade, the
re has been progress in the diagnosis, staging and biology of mesothel
ioma. Treatment remains controversial and ranges from supportive care
alone to aggressive multimodality therapy, Prospective clinical trials
in carefully staged patients are needed to determine what approaches
to treatment may confer a survival benefit.